IBB Ventures is a venture capital firm that specializes in providing equity financing to innovative biotech startups and young companies in the life sciences sector. The firm focuses on companies with a strong scientific base, primarily in Germany, and supports them through the development stages towards market entry.

IBB Ventures (www.ibbventures.de) has been providing venture capital to innovative Berlin-based companies since 1997 and has established itself as the market leader in early stage financing. The funds are primarily used for development and market launch of innovative products or services as well as for business concepts from creative industries. In addition to the two VC funds for technology and creative companies with a volume of EUR 90 million, an impact VC fund with a volume of EUR 30 million has been in the investment phase since 2022. All VC funds are financed by the Investitionsbank Berlin (IBB) and the European Regional Development Fund (ERDF), managed by the State of Berlin.

Getsurance

Creators Media

moviepilot.de

mysportgroup GmbH

clipkit

dentolo

emmy

Flexperto

Spark Networks SE

Tausendkind

test IO

Thermondo

Tracks

IBB Ventures

🚀 We are excited to announce our recent investment in Daato, the holistic and flexible software platform to power your sustainability management!

👏 Congrats to the team around Satya Kamal Raparthi and Thilo Hitz, our co-investors from kopa ventures (formerly Wi Venture) and neosfer, as well as our very own Clemens Kabel and Cindy Adrienne Beckel!

#ibbventures #impact #funding #berlin #saas


 👋  Exciting news! We are thrilled to announce that Katrin Robeck and Markus Lehmann will join the management team starting in July. Their expertise and commitment will make a significant contribution to the generation change and diversity of our management team.
 
Katrin Robeck brings a vast amount of leadership experience from the Berlin.Industrial.Group, where she is Managing Director of the Corporate Service unit. Her diverse experience in the areas of technology and management make her the ideal addition to our team.
 
Markus Lehmann is no stranger to IBB Ventures. With over 20 years of experience, especially as Finance Director he brings a solid base of knowhow and expertise to drive our business strategies forward.

🙏 We would like to thank our current management team, Marco Zeller and Roger Bendisch, for more than 25 years of successful work, with which they have made an invaluable contribution to the development of IBB Ventures and the entire Berlin startup ecosystem.
 
We look forward to an exciting future with Katrin Robeck, Markus Lehmann and the entire team at IBB Ventures, who are making an important contribution to the thriving startup scene in Berlin!

👏 We are excited that our portfolio company Aignostics today announced a strategic collaboration with Bayer on several artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development. 

Aignostics is a spin-off from one of the world’s leading hospitals, Charité - Universitätsmedizin Berlin, and a global leader in using computational pathology to transform complex biomedical data into biology insights.

🚀 We are proud to announce our recent impact investment in Quantistry, an innovator in the field of chemical simulations!

👏 Congrats to the team around Marcel Quennet, Arturo Robertazzi and Stefan Kupferberg, our co-investors from Ananda Impact Ventures, Chemovator/BASF, as well as our very own Marvin Martsch!

#ibbventures #impactvc #funding #berlin

DE:IBBVENTURES

IBB Ventures

Analysis Not Available